Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure

Circulation

Volumn 111, Issue 19, 2005, Pages 2461-2468

  Ueland, Thor ^a,b   Yndestad, Arne ^a   Øie, Erik ^b,d   Florholmen, Geir ^c   Halvorsen, Bente ^a   Frøland, Stig S ^a,b   Simonsen, Svein ^b   Christensen, Geir ^c   Gullestad, Lars ^e   Aukrust, Pål ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

^e VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

Heart failure; Immunohistochemistry; Immunology; Molecular biology; Myocytes

Indexed keywords

MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

EID: 21044452012     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000165119.62099.14     Document Type: Article

References (29)

1. Aukrust P, Damas JK, Gullestad L. Immunomodulating therapy: new treatment modality in congestive heart failure. Congest Heart Fail. 2003;9:64-69.
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
3. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627-635.
4. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-1391.
5. Yndestad A, Kristian DJ, Geir EH, Holm T, Haug T, Simonsen S, Froland SS, Gullestad L, Aukrust P. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res. 2002;54:175-182.
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15:2-12.
7. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
8. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
9. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999;25:525-534.
10. Oie E, Vinge LE, Yndestad A, Sandberg C, Grogaard HK, Attramadal H. Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats. Circulation. 2000;101:415-422.
11. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess: possible role in bone homeostasis. Eur J Endocrinol. 2001;145:685-690.
12. Aukrust P, Muller F, Lien E, Nordoy I, Liabakk NB, Kvale D, Espevik T, Froland SS. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179:74-82.
13. Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, Tasken K, Froland SS, Muller F. Increased activation of protein kinase A type 1 contributes to the T cell deficiency in common variable immunodeficiency. J Immunol. 1999;162:1178-1185.
14. Stylianou E, Aukrust P, Muller F, Nordoy I, Froland SS. Complex effects of interferon-alpha on the cytokine network in HIV infection: possible contribution to immunosuppression. Cytokine. 2001;14:56-62.
15. Andersen GO, Skomedal T, Enger M, Fidjeland A, Brattelid T, Levy FO, Osnes JB. Alpha1-AR-mediated activation of NKCC in rat cardiomyocytes involves ERK-dependent phosphorylation of the cotransporter. Am J Physiol Heart Circ Physiol. 2004;286:H1354-H1360.
16. Oie E, Vinge LE, Tonnessen T, Grogaard HK, Kjekshus H, Christensen G, Smiseth OA, Attramadal H. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol. 1997;273:H1727-H1736.
17. Halvorsen B, Staff AC, Ligaarden S, Prydz K, Kolset SO. Lithocholic acid and sulphated lithocholic acid differ in the ability to promote matrix metalloproteinase secretion in the human colon cancer cell line CaCo-2. Biochem J. 2000;349:189-193.
18. Florholmen G, Andersson KB, Yndestad A, Austbo B, Henriksen UL, Christensen G. Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. Acta Physiol Scand. 2004;180:133-142.
19. Halvorsen B, Ranheim T, Nenseter MS, Huggett AC, Drevon CA. Effect of a coffee lipid (cafestol) on cholesterol metabolism in human skin fibroblasts. J Lipid Res. 1998;39:901-912.
20. Staff AC, Ranheim T, Henriksen T, Halvorsen B. 8-Iso-prostaglandin f(2alpha) reduces trophoblast invasion and matrix metalloproteinase activity. Hypertension. 2000;35:1307-1313.
21. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F. Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun. 2003;310:774-778.
22. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med. 2002;12:97-101.
23. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
24. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin: clinical relevance and potential applications. Eur J Endocrinol. 2001;145:681-683.
25. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P. Effect of metoprolol on cytokine levels in chronic heart failure: a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J. 2001;141:418-421.
26. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220-225.
27. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194.
28. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-1028.
29. Ueland T, Jemtland R, Godang K, Dickstein K, Kjekshus J, Hognestad A, Squire I, Gullestad L, Bollerslev J, Aukrust P. The prognostic value of osteoprotegerin in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976.